Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry. (24th February 2023)

• Record Type: Journal Article
• Authors: Argyriou, Andreas A.; Dermitzakis, Emmanouil V.; Xiromerisiou, Georgia; Rallis, Dimitrios; Soldatos, Panagiotis; Litsardopoulos, Pantelis; Vikelis, Michail
• Is Part Of: European journal of neurology. Volume 30:Number 5(2023)
• Page Start: 1435
• Page End: 1442
• Publication Date: 2023-02-24
• Subjects: CGRP -- chronic migraine -- efficacy/safety -- episodic migraine -- fremanezumab -- monoclonal antibodies -- prevention; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15740
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Objective: To prospectively assess the efficacy and safety of fremanezumab for migraine prophylaxis in patients with failure of at least three previous preventive treatments. Changes in disability as quality‐of‐life outcomes after fremanezumab treatment were also examined. Methods: Two hundred and four patients with either high‐frequency EM (HFEM) or chronic migraine (CM), who attained at least three consecutive monthly sessions with fremanezumab 225 mg and otherwise met the inclusion criteria, were included in the study. The crude response (at least 50% reduction in monthly headache days [MHD]) rates to fremanezumab were assessed. Scores in the following efficacy outcomes were then compared from baseline to the last efficacy evaluation follow‐up: (i) MHD, (ii) monthly days with moderate/severe peak headache intensity, and (iii) monthly days with intake of abortive medication. The disability was evaluated with the Migraine Disability Assessment; the quality of life (QOL) status was assessed with the Headache Impact‐6 Test, and the EQ‐5D questionnaire. Results: In the majority of HFEM cases ( n = 81/97; 83.5%) and CM patients ( n = 67/107; 62.6%), fremanezumab proved effective in reducing the MHDs by at least 50% and was associated with clinically meaningful improvement in all other efficacy variables. The migraine‐related disability experienced by our patients decreased and their QOL increased. We recorded just 36 cases reporting mild adverse events, including pain, rash or pruritus ( n = 26), flu‐like symptoms ( n = 8), and hair loss ( n = 2). Conclusion: With our prospective results, we provide further real‐world data to support the favorable benefit/risk profile of fremanezumab in the prophylaxis of both HFEM and CM.